Profound Medicl (NYSE:PROF) had its price objective increased by Raymond James from $35.00 to $38.00 in a report published on Friday, The Fly reports. They currently have a strong-buy rating on the stock.

Several other brokerages have also commented on PROF. Mackie lowered Profound Medicl from a buy rating to a hold rating in a research note on Tuesday, April 7th. Cowen began coverage on Profound Medicl in a research note on Wednesday, April 1st. They issued an outperform rating and a $15.00 price objective on the stock. Finally, Zacks Investment Research lowered Profound Medicl from a buy rating to a hold rating in a research note on Saturday, May 30th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Profound Medicl has a consensus rating of Buy and an average price target of $22.33.

Shares of PROF stock opened at $16.08 on Friday. The stock’s fifty day simple moving average is $12.82 and its 200 day simple moving average is $12.49. Profound Medicl has a one year low of $5.00 and a one year high of $20.60.

Profound Medicl (NYSE:PROF) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.03. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.62 million.

A number of institutional investors have recently bought and sold shares of PROF. Gagnon Securities LLC bought a new stake in shares of Profound Medicl during the fourth quarter worth $7,630,000. Redmile Group LLC bought a new stake in shares of Profound Medicl during the first quarter worth $3,896,000. Gagnon Advisors LLC bought a new stake in shares of Profound Medicl during the fourth quarter worth $2,548,000. EAM Global Investors LLC bought a new stake in shares of Profound Medicl during the first quarter worth $2,125,000. Finally, Blackcrane Capital LLC bought a new stake in shares of Profound Medicl during the first quarter worth $2,167,000.

Profound Medicl Company Profile

Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.

Featured Story: Street Name

The Fly

Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with MarketBeat.com's FREE daily email newsletter.